Correlation Engine 2.0
Clear Search sequence regions
Bookmark Forward

QuickView for Terazosin (compound)

Name: Terazosin
PubChem Compound ID: 11429311
Molecular formula: C19H25N5O4
Molecular weight: 393.457 g/mol
Name: Terazosin
Name (isomeric): DB01162
Drug Type: small molecule
Terazosine [INN-French]; Terazosin hydrochloride; Terazosin HCl; Abbott 45975; Terazosinum [INN-Latin]; Trazosin HCl; Terazosine; Terazosina [INN-Spanish]
Brand: Hytracin, Vasomet, Vicard, Hytrinex, Itrin, Urodie, Heitrin, Hytrin, Blavin, Fosfomic, Flumarc
Category: Antineoplastic Agents, Adrenergic alpha-Antagonists
CAS number: 63590-64-7
Indication: For the treatment of symptomatic BPH and mild to moderate hypertension.
Terazosin, classified as a quinazoline, is similar to doxazosin and prazosin. As an α-adrenergic blocking agent, terazosin is used to treat hypertension and BPH. Terazosin produces vasodilation and reduces peripheral resistance but in general has only a slight effect on cardiac output. The antihypertensive effect with chronic dosing is not us...
show more »
Mechanism of Action:
In general, α1-adrenergic receptors mediate contraction and hypertrophic growth of smooth muscle cells. α1-Receptors are 7-transmembrane domain receptors coupled to G proteins, Gq/11. Three α1-receptor subtypes, which share approximately 75% homology in their transmembrane domains, have ...
show more »
Absorption: Essentially completely absorbed in man (90% bioavailability).
Protein binding: 90-94%
Biotransformation: Hepatic. One of the four metabolites identified (piperazine derivative of terazosin) has antihypertensive activity.
Route of elimination: Approximately 10% of an orally administered dose is excreted as parent drug in the urine and approximately 20% is excreted in the feces.
Half Life: 12 hours
Toxicity: LD50=259.3mg/kg (IV in mice)
Affected organisms: Humans and other mammals
Drug interaction:
PropranololIncreased risk of hypotension. Initiate concomitant therapy cautiously.
RituximabAdditive antihypertensive effects may occur. Increased risk of hypotension. Consider withholding Terazosin for 12 hours prior to administration of Rituximab.
AlfuzosinAdditive antihypertensive effects may occur. Increase risk of orthostatic hypotension and syncope. Concomitant therapy should be avoided.
AcebutololIncreased risk of hypotension. Initiate concomitant therapy cautiously.
NebivololIncreased risk of hypotension. Initiate concomitant therapy cautiously.
show more »